NO20052495L - Induserbar ligand for alfa1 beta1 integrin og anvendelse derav. - Google Patents

Induserbar ligand for alfa1 beta1 integrin og anvendelse derav.

Info

Publication number
NO20052495L
NO20052495L NO20052495A NO20052495A NO20052495L NO 20052495 L NO20052495 L NO 20052495L NO 20052495 A NO20052495 A NO 20052495A NO 20052495 A NO20052495 A NO 20052495A NO 20052495 L NO20052495 L NO 20052495L
Authority
NO
Norway
Prior art keywords
alpha1
beta1 integrin
inducible ligand
inducible
ligand
Prior art date
Application number
NO20052495A
Other languages
English (en)
Other versions
NO20052495D0 (no
Inventor
Dominic Cosgrove
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of NO20052495D0 publication Critical patent/NO20052495D0/no
Publication of NO20052495L publication Critical patent/NO20052495L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Det beskrives identifisering og bruk av midler, særlig peptider og monoklonale antistoffer, som bryter interaksjonen mellom Collagen XIII og alfal betal-integrin.
NO20052495A 2002-11-01 2005-05-24 Induserbar ligand for alfa1 beta1 integrin og anvendelse derav. NO20052495L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42329702P 2002-11-01 2002-11-01
PCT/US2003/034818 WO2004041846A2 (en) 2002-11-01 2003-10-31 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

Publications (2)

Publication Number Publication Date
NO20052495D0 NO20052495D0 (no) 2005-05-24
NO20052495L true NO20052495L (no) 2005-07-25

Family

ID=32312635

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052495A NO20052495L (no) 2002-11-01 2005-05-24 Induserbar ligand for alfa1 beta1 integrin og anvendelse derav.

Country Status (14)

Country Link
US (2) US7348002B2 (no)
EP (1) EP1562632B1 (no)
JP (1) JP2006516024A (no)
KR (1) KR20050084921A (no)
CN (1) CN1826137A (no)
AU (1) AU2003287435A1 (no)
BR (1) BR0315054A (no)
CA (1) CA2504125A1 (no)
EA (1) EA200500576A1 (no)
IS (1) IS7832A (no)
MX (1) MXPA05004563A (no)
NO (1) NO20052495L (no)
PL (1) PL376714A1 (no)
WO (1) WO2004041846A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004563A (es) * 2002-11-01 2005-07-26 Boys Town Nat Res Hospital Ligando inducible para la integrina alfa1beta1 y usos.
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
US7718765B2 (en) * 2005-11-16 2010-05-18 The University Of Tennessee Research Foundation Methods of treating fibrosing diseases by induction of immune tolerance
PL2200622T5 (pl) * 2007-09-19 2016-08-31 Pluristem Ltd Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
ES2529706T3 (es) * 1999-06-01 2015-02-24 Biogen Idec Ma Inc. Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios
GB2356401A (en) * 1999-11-19 2001-05-23 Proteom Ltd Method for manipulating protein or DNA sequence data
MXPA05004563A (es) * 2002-11-01 2005-07-26 Boys Town Nat Res Hospital Ligando inducible para la integrina alfa1beta1 y usos.

Also Published As

Publication number Publication date
NO20052495D0 (no) 2005-05-24
EP1562632A2 (en) 2005-08-17
CN1826137A (zh) 2006-08-30
EP1562632A4 (en) 2007-01-17
US7662382B2 (en) 2010-02-16
WO2004041846A3 (en) 2005-04-28
BR0315054A (pt) 2005-08-16
MXPA05004563A (es) 2005-07-26
EP1562632B1 (en) 2012-12-05
CA2504125A1 (en) 2004-05-21
AU2003287435A2 (en) 2004-06-07
US20040253241A1 (en) 2004-12-16
US7348002B2 (en) 2008-03-25
KR20050084921A (ko) 2005-08-29
PL376714A1 (pl) 2006-01-09
EA200500576A1 (ru) 2006-02-24
WO2004041846A2 (en) 2004-05-21
IS7832A (is) 2005-04-29
US20080227121A1 (en) 2008-09-18
AU2003287435A1 (en) 2004-06-07
JP2006516024A (ja) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20052495L (no) Induserbar ligand for alfa1 beta1 integrin og anvendelse derav.
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
DK0921395T3 (da) Assays til måling af proteinfragmenter i biologiske medier
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
WO2004041865A3 (en) Stabilized single domain antibodies
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
ATE438662T1 (de) Verbesserte fc-fusionsproteine
DE50311921D1 (de) Mikropartikel mit cd28-spezifischen monoklonalen antikoerpern
DE602004017864D1 (de) Trägerproteine für impfstoffe
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
DE60216278D1 (de) Polyoxyalkylen-ammoniumsalze und ihre verwendung als antistatika
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
DK1183043T3 (da) Lægemiddel til lokal anvendelse, som indeholder fibrinogen, thrombin, transglutaminaser og inhibitorer for protease
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
DE60222149D1 (de) Referenzkontrolle für hochempfindliche tests des c-reaktiven proteins
HK1076472A1 (en) Altering memory by affecting staufen function

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application